



**HAL**  
open science

## Peripartum bleeding management in a patient with CalDAG-GEFI deficiency

M. Canault, P. Saultier, Sixtine Faure, M. Poggi, A. Nurden, P. Nurden, P.  
Morange, Marie-Christine Alessi, J-C. Gris

► **To cite this version:**

M. Canault, P. Saultier, Sixtine Faure, M. Poggi, A. Nurden, et al.. Peripartum bleeding management in a patient with CalDAG-GEFI deficiency. *Haemophilia*, 2017, 23 (6), pp.e533-e535. 10.1111/hae.13352 . hal-01753798

**HAL Id: hal-01753798**

**<https://amu.hal.science/hal-01753798v1>**

Submitted on 6 Apr 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Peripartum bleeding management in a patient with CalDAG-GEFI deficiency**

2  
3 Matthias Canault<sup>1</sup>, Paul Saultier<sup>1</sup>, Sixtine Fauré<sup>1</sup>, Marjorie Poggi<sup>1</sup>, Alan T Nurden<sup>2</sup>, Paquita  
4 Nurden<sup>2</sup>, Pierre-Emmanuel Morange<sup>1,3</sup>, Marie-Christine Alessi<sup>1,3\*</sup>, Jean-Christophe Gris<sup>4\*</sup>

5  
6  
7  
8 <sup>1</sup> Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France

9 <sup>2</sup> Institut-Hospitalo-Universitaire LIRYC, Plateforme Technologique et d'Innovation Biomédicale,  
10 Hôpital Xavier Arnoz, Pessac, France

11 <sup>3</sup> APHM, CHU Timone, French Reference Centre for Rare Platelet Disorders, Marseille, France.

12 <sup>4</sup> Laboratoire d'hématologie, Groupe Hospitalo-Universitaire Caremeau, Nîmes, France

13  
14 \* These authors contributed equally to this study

15  
16 Correspondence to:

17 Matthias Canault

18 UMR Inserm 1062, INRA 1260, Aix-Marseille Univ

19 Nutrition, Obesity and Risk of Thrombosis (NORT) laboratory

20 Faculté de Médecine Timone, 27 boulevard Jean-Moulin

21 13385 Marseille Cedex 05

22 [matthias.canault@univ-amu.fr](mailto:matthias.canault@univ-amu.fr)

23 Tel: +33 491 324 507

24 Fax: +33 491 254 336

25  
26  
27 **Essentials**

- 28 • Some platelet disorders increase risk of haemorrhage during pregnancy and delivery.  
29 • Management of bleeding diathesis during the course of pregnancy in CalDAG-GEFI  
30 deficiency.  
31 • Severe bleeding occurred in the postpartum period similar to that in women with  
32 Glanzmann's thrombasthenia.  
33 • A planned bleeding prevention strategy is required for pregnant women with CalDAG-  
34 GEFI deficiency.

35 Word count: 955

36

37 *To the editor,*

38 Pregnant women with inherited platelet disorders are at high risk of life-threatening  
39 haemorrhage during delivery. Foetuses and newborns can also be affected, and be at risk of  
40 bleeding complications (1, 2). Here we describe bleeding diathesis and its management during  
41 the course of pregnancy in a young woman with severe mucocutaneous bleeding and platelet  
42 dysfunction caused by calcium and diacylglycerol-guanine exchange factor I (CalDAG-GEFI)  
43 deficiency recently characterised by several groups (3-6). The patient was explored after  
44 informed written consent was obtained, in accordance with the Declaration of Helsinki.

45 The propositus was born in 1994 from asymptomatic consanguineous parents (cousins). She  
46 experienced easy bruising and recurrent epistaxis from early childhood (Fig. 1A) with an  
47 International Society on Thrombosis and Haemostasis (ISTH) bleeding score (7) of 5. She  
48 carried a homozygous frameshift mutation c.199\_200delAA (p.N67Lfs\*24) within the  
49 CalDAG-GEFI coding gene, *RASGRP2* (6). Westbury *et al.* recently described her clinical  
50 features and platelet phenotypes, emphasising a platelet aggregation defect after stimulation  
51 with intermediate- and low-dose agonists.

52 Western-blot analysis revealed absence of CalDAG-GEFI in the patient's platelets (Fig. 1B)  
53 and in GripTite 293 MSR cells expressing the p.L67 variant compared with the p.N67 (wild-  
54 type) and the p.G248W (previously reported (3)) variants (Fig. 1C).

55 Between ages 5 and 11 years the propositus was repeatedly hospitalised for intractable  
56 mucocutaneous bleeding, with sometimes acute anaemia requiring platelet/red blood cell  
57 (RBC) transfusions, recombinant factor VIIa (rFVIIa) injection (90 µg/kg), tranexamic acid  
58 and iron supplementation (Fig. 1A). At menarche (age 11 years), she experienced severe  
59 menorrhagia, treated with tranexamic acid. Severe autoimmune thrombocytopenia (6 G/l with  
60 strongly positive anti-GPIIb/IIIa (anti- $\alpha_{IIb}\beta_3$  integrin) autoantibodies) was concomitantly

61 evidenced. Evans' syndrome was characterised one year later (haemoglobin 63 g/l, platelet  
62 count 59 G/l) with further diagnosis of systemic lupus erythematosus (SLE) complicated by  
63 lupus nephropathy at age 13 years. She was treated with initial  $\gamma$ -globulin infusion,  
64 corticosteroids, hydroxychloroquine and enalapril.

65 At age 15 years she was hospitalised for acute anaemia (46 g/l haemoglobin) due to severe  
66 menorrhagia. Her platelet count was 500 G/l, and bleeding was treated with platelet/RBC  
67 transfusions and noregestrol. Treatment on exit was iron supplementation, prednisone,  
68 enalapril, and hydroxochloroquine.

69 At age 19 years she received progestin oral contraception to treat hypermenorrhea. Her  
70 chronic treatment was maintained.

71 A first pregnancy was diagnosed a few months later. She displayed normal blood pressure  
72 values and no sign of oedema. Platelet count was 252 G/l, and she tested positively for  
73 antinuclear antibodies 1/320, and negative for anti-DNA and antiphospholipid antibodies.  
74 Creatinine level was 52  $\mu$ M (normal range 45–90  $\mu$ M) with no proteinuria. The patient had a  
75 monthly follow-up, without emergence of any abnormal symptom (bleeding, SLE flare,  
76 cytopenia or manifestation of renal disease).

77 She was hospitalised for spontaneous onset of labour at 38 weeks plus 6 days (platelet count  
78 277 G/l, haemoglobin 145 g/l). Spinal or epidural anaesthesia was contraindicated, and  
79 patient-controlled analgesia with remifentanil was initiated. As labour progressed,  
80 prophylactic transfusion of 6 platelet concentrates and continuous intravenous tranexamic  
81 acid infusion (10 mg.kg<sup>-1</sup> bolus, then 1 mg/kg/h) were prescribed. She gave birth after 8 h of  
82 labour by vaginal delivery, to a healthy male newborn with normal neonatal blood cell counts.  
83 Artificial placental delivery had to be performed under general anaesthesia. Sulprostone was  
84 used to reverse uterus atony and prevent postpartum haemorrhage. No maternal or neonate  
85 bleeding was evidenced. One prophylactic transfusion of 6 platelet concentrates was

86 performed early post-delivery. The patient was monitored for 5 days, and was released from  
87 hospital without any haemostatic maintenance treatment.

88 Severe metrorrhagia occurred on day 11 *post partum*. A single emergency transfusion of 6  
89 platelet concentrates was administered together with a continuous tranexamic acid infusion  
90 (Fig. 1A), resulting in prompt positive clinical effects. The patient left the hospital on day 13  
91 *post partum*; her treatment was prednisone (10 mg/d), hydroxochloroquine (400 mg/d), oral  
92 tranexamic acid (1 g each 8 h for 3 days).

93 She underwent an emergency hospitalisation 38 days *post partum* for a severe haemorrhagic  
94 first post-pregnancy menstrual period with expulsion of clots by the vaginal route. Platelet  
95 count was within normal ranges. Platelets and RBC transfusions, intravenous tranexamic acid  
96 and fluid infusions allowed haemodynamic stabilisation, but showed moderate haemostatic  
97 efficacy. A single rFVIIa injection (90 µg/kg) stopped abnormal bleeding. The patient left the  
98 hospital 4 days later.

99 This report is the first to describe the management of pregnancy and parturition in a patient  
100 with homozygous CalDAG-GEFI deficiency. A deficit in CalDAG-GEFI leads to integrin  
101 activation defects (3-5). However, unlike in Glanzmann's thrombasthenia (GT), CalDAG-  
102 GEFI-deficient platelets achieve full aggregation when stimulated with high doses of strong  
103 agonists (TRAP-6 and collagen). This suggests that the risk of bleeding complications in these  
104 patients might be lower than in women with GT.

105 As in other inherited platelet disorders (1), the course of pregnancy in this context was not  
106 altered despite the added diagnosis of SLE. Repeated platelet transfusions in the delivery  
107 period prevented haemorrhage. Close follow-up and a preventive haemostatic strategy in  
108 women with CalDAG-GEFI deficiency are required not only during the primary postpartum  
109 period (within 48 h of birth), but also from 48 h to several weeks post-birth until menses  
110 resume. Maintaining tranexamic acid treatment might be of benefit throughout this period.

111 The severe bleeding episode experienced at resumption of menses was only partially  
112 controlled by platelet and RBC transfusions. Injection of single-dose rFVIIa demonstrated a  
113 significant effect in stopping haemorrhage. Thus rFVIIa may be considered as a strategy to  
114 manage the haemorrhagic risk in women with CalDAG-GEFI deficiency at delivery and  
115 during the following days.

116 In conclusion, this case illustrates for the first time that CalDAG-GEFI deficiency carries an  
117 increased risk of severe bleeding during the peripartum period. Prolonged monitoring and a  
118 planned preventive haemostatic strategy are accordingly required to minimise bleeding in  
119 these high-risk pregnant women.

## 120 **Acknowledgements**

121 We thank J.P. Balducchi, S. Baron-Joly, N. Catteau, R. Salet, A.L. Ladra-Delenne, R. de  
122 Tayrac, S. Ripart, J.M. Ferrer, and L. Mattatia for their expert medical help in the acute and  
123 chronic management of the patient. We also thank N. Saut of the Laboratoire d'Hématologie,  
124 Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille) for gene sequencing.

125 M. Canault and J-C. Gris performed the research, designed the research study, took part in the  
126 clinical characterisation of patients, analysed the data and wrote the paper. P. Saultier, S.  
127 Faure and M. Poggi performed the research, analysed the data and wrote the paper. A.T.  
128 Nurden, P. Nurden, P.E. Morange and M-C. Alessi designed the research study, analysed the  
129 data and wrote the paper. The authors have no competing interests

## 130 **References**

- 131 1. Civaschi E, Klersy C, Melazzini F, Pujol-Moix N, Santoro C, Cattaneo M, et al.  
132 Analysis of 65 pregnancies in 34 women with five different forms of inherited platelet  
133 function disorders. *Br J Haematol.* 2015 Aug;170(4):559-63. PubMed PMID: 25899604.
- 134 2. Noris P, Schlegel N, Klersy C, Heller PG, Civaschi E, Pujol-Moix N, et al. Analysis of  
135 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia.  
136 *Haematologica.* 2014 Aug;99(8):1387-94. PubMed PMID: 24763399. PMCID: 4116839.

- 137 3. Canault M, Ghalloussi D, Grosdidier C, Guinier M, Perret C, Chelghoum N, et al.  
138 Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe  
139 bleeding. *The Journal of experimental medicine*. 2014 Jun 30;211(7):1349-62. PubMed  
140 PMID: 24958846. PMCID: 4076591.
- 141 4. Kato H, Nakazawa Y, Kurokawa Y, Kashiwagi H, Morikawa Y, Morita D, et al.  
142 Human CalDAG-GEFI deficiency confers severe bleeding tendency and delayed  
143 alphaIIbbeta3 activation velocity. *Blood*. 2016 Sep 23. PubMed PMID: 27663674.
- 144 5. Lozano ML, Cook A, Bastida JM, Paul DS, Irwin G, Cid AR, et al. Novel mutations in  
145 RASGRP2 encoding for CalDAG-GEFI abrogate Rap1 activation causing platelet  
146 dysfunction. *Blood*. 2016 May 27. PubMed PMID: 27235135.
- 147 6. Westbury SK, Canault M, Greene D, Bermejo E, Hanlon K, Lambert MP, et al.  
148 Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe  
149 bleeding. *Blood*. 2017 Jun 21. PubMed PMID: 28637664.
- 150 7. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Collier B, James P, et al. ISTH/SSC  
151 bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding  
152 score for inherited bleeding disorders. *J Thromb Haemost*. 2010 Sep;8(9):2063-5. PubMed  
153 PMID: 20626619.
- 154 8. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes  
155 of pregnancy in Glanzmann thrombasthenia. *Haemophilia*. 2011 Sep;17(5):e858-69. PubMed  
156 PMID: 21457404.
- 157 9. Deng YJ, Huang ZX, Zhou CJ, Wang JW, You Y, Song ZQ, et al. Gene profiling  
158 involved in immature CD4+ T lymphocyte responsible for systemic lupus erythematosus.  
159 *Molecular immunology*. 2006 Mar;43(9):1497-507. PubMed PMID: 16143398.
- 160 10. Ishida D, Su L, Tamura A, Katayama Y, Kawai Y, Wang SF, et al. Rap1 signal  
161 controls B cell receptor repertoire and generation of self-reactive B1a cells. *Immunity*. 2006  
162 Apr;24(4):417-27. PubMed PMID: 16618600.

163

## 164 **Figure legends**

165 Figure 1: (A) Evolution of platelet count, haemorrhagic and autoimmune manifestations and  
166 haemostatic treatments prior to and during pregnancy/delivery. (B) Representative Western-  
167 blot for CalDAG-GEFI in platelet lysates from two healthy subjects (Controls), the patient,  
168 her mother and her father. GAPDH expression was used as equal loading and electrophoretic  
169 transfer control. (C) Representative Western-blot for CalDAG-GEFI in GripTite™ 293 MSR  
170 cells transfected with vectors coding for the wild-type, p.G248W, and p.N67Lfs\*24 variants

171 of CalDAG-GEFI. GAPDH expression was used as equal loading and electrophoretic transfer  
172 control.